MK-0626,a selective DPP-4 inhibitor,attenuates hepatic steat

发布时间：2021-03-06 04:24

　　AIM:To investigate the mechanism and in vivo effects of MK-0626,a dipeptidyl peptidase-4 inhibitor,on hepatic steatosis using ob/ob mice.METHODS:We analyzed obese（ob/ob）8-wk-old male mice that had been randomly divided into two groups of ob/ob mice（n=16 each）and were treated with1.5 or 3 mg/kg MK-0626 and two control groups of untreated ob/ob mice and lean littermates（n=16 each）.All mice were fed a normal chow diet with or without MK-0626 for either four or eight weeks.Blood samples were collect... 

【文章来源】：World Journal of Gastroenterology. 2014,20(43)

【文章页数】：9 页

【文章目录】：
INTRODUCTION
MATERIALS AND METHODS
    Animals, treatment and specimen collection
    Hepatic lipid profiles
    Biochemical and histological analysis
    RNA expression analysis of the liver specimen
    Western blotting analysis
    Statistical analysis
RESULTS
    MK-0626 treatment increased active GLP-1concentrations in the serum of ob/ob mice compared to MK-0626-untreated ob/ob mice
    MK-0626 treatment did not significantly change body weight, food intake or the ratio of liver weight to body weight in ob/ob mice
    MK-0626 treatment reduced hepatic fat content in ob/ob mice
    MK-0626 treatment increased PPARαand MTP m RNA expression and decreased the m RNA expression of SREBP-1c, SCD-1 and FAS
    MK-0626 treatment increased AMPK activation in whole liver in a dose-dependent manner
DISCUSSION
COMMENTS
    Background
    Research frontiers
    Innovations and breakthroughs
    Peer review



本文编号：3066432